SG11202100663VA - Anti-cxcr2 antibodies and uses thereof - Google Patents

Anti-cxcr2 antibodies and uses thereof

Info

Publication number
SG11202100663VA
SG11202100663VA SG11202100663VA SG11202100663VA SG11202100663VA SG 11202100663V A SG11202100663V A SG 11202100663VA SG 11202100663V A SG11202100663V A SG 11202100663VA SG 11202100663V A SG11202100663V A SG 11202100663VA SG 11202100663V A SG11202100663V A SG 11202100663VA
Authority
SG
Singapore
Prior art keywords
cxcr2 antibodies
cxcr2
antibodies
Prior art date
Application number
SG11202100663VA
Other languages
English (en)
Inventor
Doris Chen
Lynn Poulton
Adam Clarke
David Laine
Matthew Pollard
Bridget Cooksey
Anthony Doyle
Jason Gill
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of SG11202100663VA publication Critical patent/SG11202100663VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202100663VA 2018-08-01 2019-07-31 Anti-cxcr2 antibodies and uses thereof SG11202100663VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862713095P 2018-08-01 2018-08-01
PCT/US2019/044314 WO2020028479A1 (en) 2018-08-01 2019-07-31 Anti-cxcr2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11202100663VA true SG11202100663VA (en) 2021-02-25

Family

ID=67614672

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100663VA SG11202100663VA (en) 2018-08-01 2019-07-31 Anti-cxcr2 antibodies and uses thereof

Country Status (12)

Country Link
US (2) US11332534B2 (ja)
EP (1) EP3830124A1 (ja)
JP (2) JP7473531B2 (ja)
KR (1) KR20210041586A (ja)
CN (1) CN112955463A (ja)
AU (1) AU2019312576A1 (ja)
BR (1) BR112021001683A2 (ja)
CA (1) CA3108071A1 (ja)
IL (1) IL280321A (ja)
MX (1) MX2021001305A (ja)
SG (1) SG11202100663VA (ja)
WO (1) WO2020028479A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056329A1 (en) * 2020-09-10 2022-03-17 Immunome, Inc. Snx9 subfamily-targeting antibodies
EP4063384A1 (en) * 2021-03-23 2022-09-28 Ceinge Biotecnologie Avanzate SCarl Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
TWI825687B (zh) * 2021-04-26 2023-12-11 高雄醫學大學 抗ｃｘｃｒ２抗體及其用途
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
NL1003537C2 (nl) 1996-07-08 1998-01-12 Holland Railconsult B V Werkwijze voor het vervaardigen van een gebogen beglazing.
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
EP3382022A1 (en) 2007-06-01 2018-10-03 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
AU2008333985B2 (en) * 2007-11-30 2015-02-05 Kalobios Pharmaceuticals, Inc. Antibodies to the PcrV antigen of pseudomonas aeruginosa
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
AU2011328246B2 (en) 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2986642A1 (en) * 2013-04-17 2016-02-24 MorphoSys AG Antibodies targeting specifically human cxcr2
WO2015169811A2 (en) 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof
KR20180053674A (ko) * 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
AU2018224391A1 (en) 2017-02-27 2019-09-19 Monash University CXCR2 antibodies and uses thereof

Also Published As

Publication number Publication date
BR112021001683A2 (pt) 2021-05-04
MX2021001305A (es) 2021-06-23
EP3830124A1 (en) 2021-06-09
US20220348671A1 (en) 2022-11-03
JP2021532789A (ja) 2021-12-02
IL280321A (en) 2021-03-01
CN112955463A (zh) 2021-06-11
AU2019312576A1 (en) 2021-02-25
JP2024026724A (ja) 2024-02-28
KR20210041586A (ko) 2021-04-15
US11332534B2 (en) 2022-05-17
CA3108071A1 (en) 2020-02-06
WO2020028479A1 (en) 2020-02-06
JP7473531B2 (ja) 2024-04-23
US20200040089A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL282968A (en) Anti-NKG2A antibodies and their use
IL268700A (en) Anti-PHF-tau antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL281297A (en) Anti-NPR1 antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL277330A (en) Anti-IL-27 antibodies and uses thereof
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
IL283926A (en) Antibodies against alpha-synuclein and their uses
IL291550A (en) Anti-il-27 antibodies and their uses
IL291546A (en) Antibodies against kir3dl3 and their uses
IL291280A (en) Antibodies against cd371 and their uses